截至2025年8月5日收盘，双鹭药业股价报8.31元，较前一交易日下跌0.95%。当日成交量为269722手， 成交金额达2.25亿元。 根据最新公告，双鹭药业预计2025年上半年归属于上市公司股东的净利润为1亿元至1.35亿元，同比增 长237.95%至356.24%。这一业绩预增信息使得公司新增"2025中报预增"概念。 从资金流向来看，8月5日双鹭药业主力资金净流出3346.65万元，近五个交易日累计净流出1.67亿元。 风险提示：以上内容仅供参考，不构成投资建议。市场有风险，投资需谨慎。 双鹭药业主要从事生物医药的研发、生产和销售，产品涵盖基因工程药物、生化药物、化学药物等多个 领域。公司属于生物制品行业，业务涉及生物疫苗等细分领域。 ...

Core Viewpoint - China Resources Double Crane plans to invest in a new fund aimed at optimizing its strategic layout and enhancing innovation transformation while securing investment returns [1][2] Group 1: Fund Establishment - The company will collaborate with ten limited partners to establish the China Resources Medicine (Chengdu) Innovation Investment Fund with a target fundraising scale of 1 billion yuan [1] - China Resources Double Crane will contribute 40 million yuan, representing 4% of the total fund [1][2] - The fund will be managed by Shenzhen China Resources Capital Equity Investment Co., Ltd [1] Group 2: Strategic Intent - The investment aims to improve the company's ability to acquire and allocate quality resources, supporting long-term sustainable development and profitability [1] - The transaction is classified as a related party transaction due to the common control by China Resources [1][2] Group 3: Historical Context - The company previously established a similar fund in October 2017 with a total scale of 2.5 billion yuan, contributing 50 million yuan as a limited partner [2] - The first fund successfully identified and invested in projects that provided synergistic value, such as the acquisition of Tiandong Pharmaceutical, which laid a foundation for a biopharmaceutical platform [3]